Lithium plus NSAIDs: toxicity from reduced renal clearance

The mechanism

Lithium is filtered at the glomerulus and about 80 percent is reabsorbed in the proximal tubule. Clearance depends on glomerular filtration rate (GFR) and to a smaller extent tubular function. Anything that reduces GFR raises lithium levels.

Renal prostaglandins (PGE2, PGI2) maintain afferent arteriolar vasodilation and support glomerular filtration during conditions of reduced renal perfusion (dehydration, heart failure, chronic kidney disease). Under normal conditions, prostaglandin contribution to renal blood flow is small. Under stress, prostaglandins keep GFR up.

NSAIDs inhibit COX-1 and COX-2, blocking prostaglandin synthesis. In healthy euvolemic patients, this has minimal renal effect. In patients with any element of renal stress (older adults, dehydration, heart failure, existing CKD, diuretics), NSAID-induced prostaglandin inhibition reduces GFR significantly.

Reduced GFR reduces lithium clearance. Lithium levels rise. Toxicity risk increases.

Which NSAIDs matter most

Highest interaction risk:

• Indomethacin: consistently reported to raise lithium levels 30 to 60 percent.
• Ketorolac (Toradol): substantial effect; commonly used post-operatively, which is a common toxicity scenario.
• Diclofenac: 30 to 50 percent lithium level rise in some studies.

Moderate risk:

• Ibuprofen: 20 to 40 percent lithium level rise on regular use.
• Naproxen: similar to ibuprofen.
• Celecoxib (COX-2 selective): interaction is real but somewhat smaller than non-selective NSAIDs in some studies.

Possibly less interaction:

• Sulindac: some studies suggest sulindac has lower renal prostaglandin effect than other NSAIDs; interaction may be smaller. Not zero.
• Aspirin at low dose (81 mg): minimal effect on lithium levels.

Clinical scenarios that go wrong

• Older adult on stable lithium for years is prescribed ibuprofen for arthritis; over 2 to 3 weeks develops tremor, ataxia, confusion. Lithium level is 1.8 (target 0.6 to 1.2).
• Patient on lithium starts diclofenac for musculoskeletal pain; presents to ED with vomiting, tremor, lethargy.
• Post-surgical patient on lithium receives IV ketorolac; lithium level rises acutely.
• Patient self-treats headache with regular ibuprofen while on stable lithium; toxicity develops silently.

Management

Prevention:

• Educate every lithium patient about NSAID interaction at start of treatment
• Recommend acetaminophen as the default over-the-counter analgesic
• Document lithium level baseline

When NSAIDs must be used:

• Short courses (a few days) at lowest effective dose are usually tolerated
• Monitor lithium level within 5 to 7 days of starting NSAID
• Consider empirical lithium dose reduction by 25 percent when starting regular NSAID
• Adequate hydration
• Consider PPI for GI protection given SSRI-lithium-NSAID triple combinations are common

When toxicity is suspected:

• Urgent lithium level and creatinine
• Signs: coarse tremor, ataxia, confusion, GI upset, worsening
• Hold lithium if level above 1.5 with symptoms, above 2.0 regardless
• IV fluids
• Hemodialysis for level above 4.0, severe symptoms, or renal failure

Alternatives to NSAIDs in lithium patients

For acute pain:

• Acetaminophen (up to 3 to 4 grams per day in most adults)
• Suzetrigine (Journavx): Nav1.8 blocker, no renal prostaglandin effect, no lithium interaction. See our Journavx state of practice.
• Non-serotonergic opioids for severe short-term pain
• Topical NSAIDs have much less systemic absorption and lower interaction risk

For chronic pain:

• Acetaminophen
• Duloxetine (also useful for depression and anxiety, common comorbidities in lithium patients)
• Gabapentin or pregabalin for neuropathic pain (renal clearance, so dose adjust in CKD)
• Physical therapy, TENS, other non-pharmacologic

Common questions

Can I take Tylenol with my lithium? Yes. Acetaminophen does not affect lithium levels through the prostaglandin mechanism. Standard doses are safe in patients on lithium.

Is there a safe NSAID with lithium? Sulindac may have a smaller interaction than most other NSAIDs, though not zero. Aspirin at 81 mg (cardiovascular dose) has minimal lithium interaction. Otherwise, NSAIDs and lithium are best avoided for regular use.

What about occasional ibuprofen for headache? A single dose or 2 to 3 doses over a day is usually tolerated by patients on stable lithium. Regular use (daily or several times per week) is where the problem develops.

How fast does the interaction develop? Lithium level rise typically develops over 5 to 7 days of regular NSAID use. Acute single doses have modest effect. This means a patient can be on lithium plus occasional ibuprofen for a while without problems, then develop toxicity after starting daily NSAID use.

What are the early signs of lithium toxicity? Fine tremor becoming coarse, GI upset (nausea, vomiting, diarrhea), fatigue, cognitive slowing, muscle weakness. More severe: ataxia, dysarthria, confusion, myoclonus, seizures, coma. A patient on lithium who develops any of these after starting a new medication should have a lithium level checked.

Does the SSRI plus lithium plus NSAID triple combination happen a lot? Yes, especially in older adults with depression on lithium for bipolar or lithium augmentation of MDD. All three drugs are commonly prescribed. The bleeding risk (see SSRI plus NSAIDs page) plus lithium toxicity risk plus general polypharmacy makes this a combination worth reviewing.

Should I stop my lithium if I need surgery with expected NSAID use? Usually no. Discuss with the surgical team and psychiatry prescriber. Options include using non-NSAID pain management post-op, closely monitoring lithium levels for a few days after any perioperative NSAID, or holding lithium during the very acute post-op window if there is significant renal dysfunction.

Sources

• Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990;10(5):350-354.
• Handler J. Lithium and antihypertensive medication: a potentially dangerous combination. J Clin Hypertens (Greenwich). 2009;11(12):738-742.
• Chan BS, Buckley NA. Lithium: what pharmacokinetics matter. Br J Clin Pharmacol. 2015;80(2):184-193.
• Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet. 1995;29(3):172-191.
• International Society for Bipolar Disorders (ISBD) consensus on lithium monitoring.